Germline genetic testing for prostate cancer has increased, especially after the 2018 NCCN guideline expansion. Urologists are ordering more tests, particularly for younger patients and those without ...
Daniel Kwon, MD, on germline testing for prostate cancer in veterans with service-connected benefits
"We were trying to understand how veterans were making decisions about germline testing for their prostate cancer," says Daniel Kwon, MD. In this video, Daniel Kwon, MD, discusses the background and ...
Leslie M. Rickey is the first woman in Yale's Department of Urology to achieve full professor status, highlighting her expertise in female pelvic medicine and urogynecology. Women face significant ...
AI is revolutionizing urology, enhancing imaging, pathology, and endoscopy, with potential for AI-guided procedures like cystoscopy and ureteroscopy. Virtual scribes and similar AI tools aim to ...
High prevalence of VUS in prostate cancer patients undergoing RARP, potentially affecting pathological outcomes. Younger patients more likely to carry VUS, with 23.7% of study participants affected.
The combination therapy showed a 42.1% pathological complete response rate, similar to cisplatin-based chemotherapy, with no dose-limiting toxicities observed. Grade 3 or higher treatment-emergent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback